摘要
非小细胞肺癌(NSCLC)约占肺癌患者的80%。其中在肺腺癌患者中,表皮生长因子受体(EGFR)基因突变可达50%左右。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI),在东方人的肺腺癌分子靶向治疗中显示出较好的疗效和可耐受性。第1代EGFR-TKI分子口服药物吉非替尼的不良反应主要包括痤疮样皮疹、消化道反应、甲沟炎等。一般认为,此类不良反应的发生和良好的疗效及生存时间有关,本文就吉非替尼不良反应及应对措施作一综述。
Non-small cell lung cancer(NSCLC)accounts for about 80%of lung cancer patients.Among patients with lung adenocarcinoma,epidermal growth factor receptor(EGFR)gene mutation can reach about 50%.Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)has shown good efficacy and tolerability in molecular targeted therapy of oriental lung adenocarcinoma.The adverse reactions of the first-generation EGFR-TKI molecule oral medication gefitinib mainly include acne-like rash,gastrointestinal reaction,paronychia,etc.It is generally believed that the occurrence of such adverse reactions is related to good efficacy and survival time.This article reviews the adverse reactions of gefitinib and its countermeasures.
作者
胡倩倩
HU Qian-qian(Department of Pharmacy,Sir Run Run Shaw Hospital,Hangzhou 310016,China)
出处
《中国处方药》
2020年第11期19-20,共2页
Journal of China Prescription Drug
关键词
吉非替尼
不良反应
肺癌
Gefitinib
Adverse reactions
Lung cancer
